이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Erasca 관리

관리 기준 확인 3/4

Erasca's CEO는 Jonathan Lim, Jul2018 에 임명되었습니다 의 임기는 5.92 년입니다. 총 연간 보상은 $ 5.41M, 11.5% 로 구성됩니다. 11.5% 급여 및 88.5% 보너스(회사 주식 및 옵션 포함). 는 $ 66.01M 가치에 해당하는 회사 주식의 11.87% 직접 소유합니다. 66.01M. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 5.7 년입니다.

주요 정보

Jonathan Lim

최고 경영자

US$5.4m

총 보상

CEO 급여 비율	11.5%
CEO 임기	5.9yrs
CEO 소유권	11.9%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	5.7yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28

CEO 보상 분석

Jonathan Lim 의 보수는 Erasca 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$127m
Dec 31 2023	US$5m	US$623k	-US$125m
Sep 30 2023	n/a	n/a	-US$231m
Jun 30 2023	n/a	n/a	-US$236m
Mar 31 2023	n/a	n/a	-US$240m
Dec 31 2022	US$8m	US$593k	-US$243m
Sep 30 2022	n/a	n/a	-US$138m
Jun 30 2022	n/a	n/a	-US$149m
Mar 31 2022	n/a	n/a	-US$141m
Dec 31 2021	US$850k	US$498k	-US$123m
Sep 30 2021	n/a	n/a	-US$154m
Jun 30 2021	n/a	n/a	-US$119m
Mar 31 2021	n/a	n/a	-US$96m
Dec 31 2020	US$2m	US$300k	-US$102m

보상 대 시장: Jonathan 의 총 보상 ($USD 5.41M )은 US 시장( $USD 2.46M ).

보상과 수익: Jonathan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jonathan Lim (52 yo)

5.9yrs

테뉴어

US$5,407,446

보상

Dr. Jonathan E. Lim, M.D. co-founded Erasca, Inc. in July 2018 and has been its Executive Chairman since October 2018 and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Part...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jonathan Lim	Co-Founder	5.9yrs	US$5.41m	11.87% $ 71.2m
David Chacko	CFO & Chief Business Officer	3.5yrs	US$2.43m	0.091% $ 542.8k
Ebun Garner	General Counsel & Corporate Secretary	3.2yrs	US$2.02m	0.0036% $ 21.4k
Michael Varney	Chairman of Research & Development	3.8yrs	US$199.05k	0% $ 0
Nik Chetwyn	Chief Operating Officer	3.1yrs	데이터 없음	데이터 없음
Lisa Tesvich-Bonora	Chief People Officer	2.4yrs	데이터 없음	데이터 없음
Brian Baker	Senior Vice President of Finance	3.1yrs	데이터 없음	데이터 없음
Chandra Lovejoy	Chief Regulatory Affairs Officer	3.1yrs	데이터 없음	데이터 없음
Robert Shoemaker	Senior Vice President of Research	2.6yrs	데이터 없음	데이터 없음
Shannon Morris	Chief Medical Officer	2.1yrs	데이터 없음	데이터 없음
Minli Xie	Senior Vice President of Pharmaceutical Development & Operations	1.6yrs	데이터 없음	데이터 없음
Dawei Xuan	Senior Vice President of Clinical Pharmacology	1.1yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: ERAS 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jonathan Lim	Co-Founder	5.7yrs	US$5.41m	11.87% $ 71.2m
Michael Varney	Chairman of Research & Development	3.8yrs	US$199.05k	0% $ 0
George Demetri	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Alexander Casdin	Independent Director	5.9yrs	US$167.54k	0.24% $ 1.5m
Pratik Multani	Independent Director	5.9yrs	US$156.54k	0.063% $ 380.3k
Kevan Shokat	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
James Bristol	Independent Director	6yrs	US$180.08k	0.076% $ 456.5k
Julie Hambleton	Independent Director	3.3yrs	US$165.04k	0.0022% $ 13.2k
Ryan Corcoran	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Valerie Harding-Start	Independent Director	5yrs	US$165.54k	0.0081% $ 48.4k
Karen Cichowski	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Pablo Rodriguez-Viciana	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: ERAS 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.

Erasca 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Director recently bought US$182k worth of stock

Erasca, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

Co-Founder recently bought US$1.7m worth of stock

Co-Founder recently bought US$2.0m worth of stock

Co-Founder recently bought US$275k worth of stock

Recent updates

Erasca, Inc. Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Independent Director recently bought US$182k worth of stock

Price target decreased by 11% to US$6.25

New major risk - Shareholder dilution

Erasca, Inc. has completed a Follow-on Equity Offering in the amount of $159.999999 million.

New minor risk - Shareholder dilution

Erasca, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Erasca, Inc. announced that it expects to receive $45 million in funding

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Co-Founder recently bought US$1.7m worth of stock

Price target decreased by 7.4% to US$9.00

Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$2.0m worth of stock

New minor risk - Share price stability

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Co-Founder recently bought US$275k worth of stock

New minor risk - Share price stability

Price target decreased by 19% to US$11.50

Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Erasca, Inc. Further Strengthens Business Leadership with Two Key Promotions

Independent Director recently bought US$55k worth of stock

Price target decreased by 9.3% to US$15.57

Co-Founder recently bought US$284k worth of stock

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Co-Founder recently bought US$231k worth of stock

Co-Founder recently bought US$200k worth of stock

Price target decreased to US$18.60

Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces Preliminary Data for Eras-007 and Eras-601 in Braf-Driven and Ras/Mapk-Altered Solid Tumors

Erasca adds 10% ahead of R&D Day

Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Erasca, Inc.(NasdaqGS:ERAS) dropped from Russell 2000 Growth Index

Erasca, Inc. Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Erasca, Inc. Announces Key Appointments

Erasca Appoints Jean Liu to its Board of Directors

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Multiforme

Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca, Inc. has completed an IPO in the amount of $300 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령